EARNEST Partners
ARCT icon

EARNEST Partners’s Arcturus Therapeutics ARCT Stock Holding History

EARNEST Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,404
Closed -$885K – 1176
2020
Q4 		$885K Sell
20,404
-303,954
-94% -$20.6M 0.01% 207
2020
Q3 		$13.9M Buy
324,358
+53,206
+20% +$2.64M 0.12% 158
2020
Q2 		$12.7M Buy
+271,152
New +$9.35M 0.12% 155

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EARNEST Partners's ARCT Position: Q1 2021 in Review

EARNEST Partners sold out of Arcturus Therapeutics (ARCT) in Q1 2021, closing a stake of 20,404 shares — an estimated $885K sold.

EARNEST Partners first reported a position in ARCT in Q2 2020 and held it in 3 quarters. The position peaked at $13.9M in Q3 2020. 162 funds tracked by Wall St. Rank hold ARCT as of Q1 2021.

  • EARNEST Partners reported no remaining Arcturus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • EARNEST Partners sold 20,404 Arcturus Therapeutics shares in Q1 2021, an estimated $885K.
  • EARNEST Partners first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 3 quarters.
  • EARNEST Partners's Arcturus Therapeutics position peaked at $13.9M in Q3 2020.
  • 162 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2021.

Based on EARNEST Partners's 13F filing for Q1 2021, filed 17 May 2021.